[New Drug Spotlight] Imlunestrant - A next-generation oral selective estrogen receptor degrader (SERD) targeting endocrine-resistant and ER-mutant breast cancer

Imlunestrant (brand name Inluriyo®) is an oral small-molecule selective estrogen receptor degrader (SERD) developed by Eli Lilly.

[Commercial Synthesis Spotlight] Process Route Development of a Key Pyrazine Building Block

Nitrogen-containing heterocycles play a pivotal role in modern medicinal chemistry, particularly pyrazine structures, which are widely applied in oncology research and other therapeutic areas.

[New Drug Spotlight] Remibrutinib - A first-in-class oral BTK inhibitor targeting mast-cell and B-cell–mediated inflammation in CSU

Remibrutinib (trade name Rhapsido®) was approved by the U.S. FDA on September 30, 2025, for the treatment of adults with chronic spontaneous urticaria (CSU) who have an inadequate response to H1 antihistamines.

[New Drug Spotlight] Seralutinib - A Next-Generation Inhaled Tyrosine Kinase Inhibitor Targeting Pulmonary Vascular Remodeling in PAH

Seralutinib is a next-generation inhaled small-molecule tyrosine kinase inhibitor developed by Gossamer Bio and is currently in Phase 3 clinical trials for the treatment of pulmonary arterial hypertension (PAH).

[Commercial Synthesis Spotlight] Development of a Manufacturing Route toward AMG 193

AMG 193 (Anvumetostat, Figure 1) is an MTA-cooperative PRMT5 inhibitor currently in clinical development for the treatment of MTAP-deleted cancers.

[New Drug Spotlight] Afuresertib - An oral ATP-competitive pan-AKT inhibitor blocking PI3K/AKT signaling to counter tumor survival and resistance

Afuresertib is an oral, ATP-competitive pan-AKT inhibitor originally from GSK and now developed by Laekna; currently in late-stage trials for solid tumors (e.g., HR+/HER2- breast cancer and mCRPC).

[Commercial Synthesis Spotlight] Development of a Scalable Synthetic Route for Enarodustat

Enarodustat is an orally active hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitor developed by Japan Tobacco for the treatment of renal anemia associated with chronic kidney disease (CKD).

[New Drug Spotlight] Nerandomilast: A First-in-Class Selective PDE4B Inhibitor Targeting Inflammation and Fibrosis in IPF

Nerandomilast is a novel treatment option for adults with idiopathic pulmonary fibrosis (IPF), approved by the U.S. FDA on October 7, 2025.